Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders – A systematic review and meta-analysis
Brain, Behavior, and Immunity · 2024
DOI: 10.1016/j.bbi.2024.06.003 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Brain, Behavior, and Immunity, 2024. Verfasst von Jennifer Murphy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: jennifermurphy22@rcsi.com. Hauptthemen laut MEDLINE: Biomarkers, Mental Disorders, Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: There is some evidence of an association between inflammation in the pathogenesis of mental disorders. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of chronic inflammation, which provides a more stable index of systemic inflammation than more widely used biomarkers. This review aims to synthesise studies that measured suPAR concentrations in individuals with a psychiatric disorder, to determine if these concentrations are altered in comparison to healthy participants. METHOD: Comprehensive literature searches from inception to October 2023 were conducted of five relevant databases (PubMed, Web of Science, Embase, Scopus, APA PsychInfo). Random-effects meta-analyses were performed to compare the standardised mean difference of blood suPAR levels (i.e. plasma or serum) for individuals with any psychiatric disorder relative to controls. Separate meta-analyses of suPAR levels were conducted for individuals with schizophrenia or other psychotic disorder and depressive disorder. Risk of bias was assessed using the Newcastle Ottawa Scale. Post-hoc sensitivity analyses included excluding studies at high risk of bias, and analyses of studies that measured suPAR concentrations either in serum or in plasma separately. RESULTS: The literature search identified 149 records. Ten full-text studies were screened for eligibility and 9 studies were included for review. Primary analyses revealed no significant difference in suPAR levels between individuals with any psychiatric disorder compared to controls (k = 7, SMD = 0.42, 95 % CI [-0.20, 1.04]). However, those with depressive disorder had elevated suPAR levels relative to controls (k = 3, SMD = 0.61, 95 % CI [0.34, 0.87]). Similarly, secondary analyses showed no evidence of a significant difference in suPAR levels in individuals with any psychiatric disorder when studies at high risk of bias were excluded (k = 6, SMD = 0.54, 95 % CI [-0.14, 1.22]), but elevated suPAR concentrations for those with schizophrenia or other psychotic disorder were found (k = 3, SMD = 0.98, 95 % CI [0.39, 1.58]). Furthermore, studies that analysed plasma suPAR concentrations found elevated plasma suPAR levels in individuals with any psychiatric disorder relative to controls (k = 5, SMD = 0.84, 95 % CI [0.38, 1.29]), while studies measuring serum suPAR levels in any psychiatric disorder did not find a difference (k = 2, SMD = -0.61, 95 % CI [-1.27, 0.04]). For plasma, elevated suPAR concentrations were also identified for those with schizophrenia or other psychotic disorder (k = 3, SMD = 0.98, 95 % CI [0.39, 1.58]). DISCUSSION: When studies measuring either only serum or only plasma suPAR were considered, no significant difference in suPAR levels were observed between psychiatric disorder groups, although significantly elevated suPAR levels were detected in those with moderate to severe depressive disorder. However, plasma suPAR levels were significantly elevated in those with any psychiatric disorder relative to controls, while no difference in serum samples was found. A similar finding was reported for schizophrenia or other psychotic disorder. The plasma findings suggest that chronic inflammatory dysregulation may contribute to the pathology of schizophrenia and depressive disorder. Future longitudinal studies are required to fully elucidate the role of this marker in the psychopathology of these disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: jennifermurphy22@rcsi.com.
- Department of Psychiatry, University College Dublin, Ireland.
- Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; Centre for Public Health, Queen's University Belfast, United Kingdom.
- Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland.
- Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland; SFI FutureNeuro Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Psychiatry, University College Dublin, Ireland; Department of Psychiatry, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Zitieren
APA
Murphy, J., Zierotin, A., Mongan, D., Healy, C., Susai, S. R., O'Donoghue, B., Clarke, M., O'Connor, K., Cannon, M., & Cotter, D. R. (2024). Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders – A systematic review and meta-analysis. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2024.06.003
Vancouver
Murphy J, Zierotin A, Mongan D, Healy C, Susai SR, O'Donoghue B, et al. Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders – A systematic review and meta-analysis. Brain, Behavior, and Immunity. 2024. doi:10.1016/j.bbi.2024.06.003
BibTeX
@article{Murphy2024,
author = {Murphy, Jennifer and Zierotin, Anna and Mongan, David and Healy, Colm and Susai, Subash R and O'Donoghue, Brian and Clarke, Mary and O'Connor, Karen and Cannon, Mary and Cotter, David R},
title = {Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders – A systematic review and meta-analysis},
journal = {Brain, Behavior, and Immunity},
year = {2024},
doi = {10.1016/j.bbi.2024.06.003}
}
EUVIMED